| Can Endangered Biosimilar Markets be Rescued? The Need to Bridge Competing Interests for Long-Term Gain T Barcina Lacosta, AG Vulto, F Turk, I Huys, S Simoens BioDrugs 38 (3), 325-329, 2024 | 1 | 2024 |
| Leveraging the holistic benefits of biosimilars in Europe–part 2: how payers can safeguard the future of a healthy biosimilar market environment J Mestre-Ferrandiz, M Czech, JS Smolen, P Cornes, MS Aapro, S Danese, ... Expert Review of Pharmacoeconomics & Outcomes Research 24 (4), 509-519, 2024 | 1 | 2024 |
| Capturing the holistic value of biosimilars in Europe–part 1: a historical perspective J Mestre-Ferrandiz, M Czech, JS Smolen, P Cornes, MS Aapro, S Danese, ... Expert Review of Pharmacoeconomics & Outcomes Research 24 (2), 237-250, 2024 | 2 | 2024 |
| Biosimilars: Principles, Regulatory Framework, and Societal Aspects AG Vulto, L Barbier Pharmaceutical Biotechnology: Fundamentals and Applications, 267-281, 2024 | | 2024 |
| Lentiviral gene therapy with IGF2-tagged GAA normalizes the skeletal muscle proteome in murine Pompe disease Q Liang, EC Vlaar, JM Pijnenburg, E Rijkers, JAA Demmers, AG Vulto, ... Journal of Proteomics 291, 105037, 2024 | 1 | 2024 |
| HPR59 Evolving Global Regulatory Landscape for Approval of Biosimilars: A Structured Literature Review on Current Challenges and Future Considerations ES Car, L Barbier, A Vulto, I Huys, S Simoens Value in Health 26 (12), S263-S264, 2023 | | 2023 |
| A Belgian policy framework for best-value biological medicines Y Vandenplas, I Huys, S Simoens, A Vulto, P Van Wilder | | 2023 |
| The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis Y Vandenplas, S Simoens, P Van Wilder, AG Vulto, I Huys Health Research Policy and Systems 21 (1), 68, 2023 | 1 | 2023 |
| Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends E Car, AG Vulto, MV Houdenhoven, I Huys, S Simoens Frontiers in Pharmacology 14, 1151764, 2023 | 9 | 2023 |
| Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international … CJT Van Der Togt, B Van den Bemt, D Aletaha, R Alten, ... RMD open 9 (1), e002898, 2023 | 9 | 2023 |
| Biosimilars in Europe AG Vulto, S Simoens, I Huys MDPI-Multidisciplinary Digital Publishing Institute, 2023 | | 2023 |
| An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain T Barcina Lacosta, AG Vulto, I Huys, S Simoens Frontiers in Medicine 9, 1029040, 2023 | 8 | 2023 |
| Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis T Barcina Lacosta, AG Vulto, I Huys, S Simoens Frontiers in Pharmacology 13, 1031910, 2022 | 5 | 2022 |
| IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy Q Liang, F Catalano, EC Vlaar, JM Pijnenburg, M Stok, Y van Helsdingen, ... Molecular Therapy-Methods & Clinical Development 27, 109-130, 2022 | 14 | 2022 |
| HPR52 TNF-Alfa Inhibitor Therapies: Evaluating the Impact of Biosimilars Competition in Italy, Portugal and Spain T Barcina, A Vulto, I Huys, S Simoens Value in Health 25 (12), S242, 2022 | | 2022 |
| HSD19 Which Elements Determine Prescribing Decisions for Off-Patent Biological Medicines in Belgium? A Qualitative Study Y Vandenplas, S Simoens, P Van Wilder, A Vulto, F Turk, I Huys Value in Health 25 (12), S276-S277, 2022 | | 2022 |
| HPR116 the impact of policy measures to increase the uptake of biosimilar medicines in Belgium: A nationwide interrupted time series analysis Y Vandenplas, S Simoens, P Van Wilder, A Vulto, I Huys Value in Health 25 (12), S253, 2022 | 1 | 2022 |
| HPR144 TNF-Alfa Inhibitor Biosimilars: Qualitative Analysis of Uptake Determinants in Southern European Hospital Markets T Barcina, A Vulto, I Huys, S Simoens Value in Health 25 (12), S258, 2022 | | 2022 |
| HPR23 A Comparative Analysis of Biosimilar Competition in European Markets of TNF-Alpha Inhibitors E Car, A Vulto, I Huys, M Van Houdenhoven, S Simoens Value in Health 25 (12), S236, 2022 | | 2022 |
| How to select a best-value biological medicine? A practical model to support hospital pharmacists L Barbier, Y Vandenplas, N Boone, I Huys, R Janknegt, AG Vulto American Journal of Health-System Pharmacy 79 (22), 2001-2011, 2022 | 4 | 2022 |
Ron van SchaikProfessor Pharmacogenetics, Erasmus在 erasmusmc.nl 的电子邮件经过验证
